We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




French-German Cooperation to Improve Personalized Cancer Care

By LabMedica International staff writers
Posted on 27 Oct 2014
A leading French oncology center will be collaborating with a German manufacturer of molecular diagnostic tests to develop new approaches to personalized cancer care.

The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes 20% of its budget to research, will be cooperating with New Oncology (Cologne, Germany), the molecular diagnostics division of Blackfield AG (Cologne, Germany), a biotechnology company focusing on genome analytics, discovering modifiers of drug response, and developing next-generation diagnostics.

New Oncology developed the proprietary diagnostic platform NEOplus. More...
This is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA. In addition, NEOplus is suited to analyzing all solid tumor types.

“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Dr. Jean-Charles Soria, head of the drug development department at Gustave Roussy Cancer Campus.

“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients,” said Dr. Andreas Jenne, CEO of New Oncology.

Related Links:

Gustave Roussy Cancer Campus
New Oncology 
Blackfield AG 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.